​Clinical investigation of medical devices

Clinical investigations that must be notified to the Norwegian Directorate of Health

  • Clinical investigations of medical devices that are not CE marked
  • Clinical investigations of medical devices that are CE marked, but where the device will be used outside the scope of the intended use designated by the current CE mark

For such investigations, a notification must be sent to the Norwegian Directorate of Health prior to starting the investigation. In addition, approval from the Regional Committees for Medical and Health Research Ethics (REK) must be obtained.

Clinical investigations of CE marked medical devices used within the scope of the intended use, as designated by the CE mark, shall not be notified to the Norwegian Directorate of Health (but may still need approval from REK). If in doubt whether an investigation should be notified or not, please contact us.

Clinical documentation of medical devices

In order to affix the CE mark to a medical device the manufacturer must declare that the device conforms to the essential requirements specified in Annex ØMU I (lovdata.no) and AIMU I (lovdata.no) in the Regulation of 15 December 2005 no 1690 on medical devices (lovdata.no), which implements Annexes I and 1 in Council Directives 93/42/EEC and 90/385EEC. The manufacturer bears the sole responsibility for documenting that the medical device is safe to use and performs as intended. As part of the process to document safety and performance, a clinical evaluation must be performed. A clinical evaluation may be based on existing clinical data, depending on the nature of the existing data and the medical device. However, if existing data are not sufficient, a clinical investigation must be conducted to obtain new clinical data. For active implantable devices and class III devices, a clinical investigation must be performed unless it is duly justified to rely on existing clinical data.

The clinical investigation must be designed to obtain relevant data, including on the safety and/or performance of the device. Exploratory studies (other terminology: pilot-, feasibility-, early-, proof-of-concept studies), may not provide sufficient data to meet the regulatory requirements for CE marking, but may provide the basis for subsequent confirmatory (pivotal) studies. Regardless of study design, the clinical investigation should be notified to the Directorate of Health. 

Notification of a clinical investigation of a medical device

A notification must sent to the national competent authority (NCA) in all EEA/EU states where the investigation is going to take place (in Norway; the Norwegian Directorate of Health) at least 60 days prior to the planned initiation of the investigation. In addition, approval from the relevant ethics committee in each state must be obtained (In Norway; the Regional Committees for Medical and Health Research Ethics).

To submit a notification, please e-mail the notification form (DOC) with all mandatory attachments to medisinsk.utstyr@helsedir.no or send by mail to the Norwegian Directorate of Health, Pb 7000 St. Olavs plass, 0130 Oslo, Norway. For further information, please see our guidance document (PDF) on how to complete the notification form.

The Norwegian Directorate of Health will review the documentation and inform the sponsor of whether there are any objections to the initiation of the investigation. If the sponsor has not been notified by the Directorate of Health within 60 days of the notification, the clinical investigation may commence. The Directorate of Health may however inform the sponsor of its decision before the end of the 60 day period. If additional information has to be requested from the sponsor, the 60 day time period will be put on hold until the requested documentation has been received. 

Notification Form (DOC)

Guidance on the Notification Form (PDF)

Regulatory framework/guidance documents:

The following must be reported to the Norwegian Directorate of Health after initiation of the investigation

Serious adverse events (SAE)

All serious adverse events must fully be recorded and immediately notified to all competent authorities of the Member States in which the clinical investigation is being performed (Regulation of 15 December 2005 no 1690 on medical devices, Annexes AIMU VII and ØMU X (lovdata.no)). Sponsor must report to the Norwegian Directorate of Health, and, if the investigation takes place in other EEA countries, to the NCAs of those countries.

Link to Reporting form for SAEs

(See Guidance MEDDEVs, under 2.7 Clinical investigation, clinical evaluation, MEDDEV 2.7/3-SAE reporting form)

For guidance, please see MEDDEV 2.7/3 Clinical investigations: serious adverse reporting. Please also consult NS-EN ISO 14155:2011.

Amendments to the clinical investigation plan

Significant amendments to the clinical investigation plan must be notified to the Norwegian Directorate of Health.

Termination of the investigation

The Directorate of Health must be notified of the end of the investigation, with a justification in case of early termination.

Clinical Investigation Report

A final report for the investigation shall be submitted. Annex D of EN ISO 14155 provides guidance on the content and format of the report (informative only).

For questions, please contact us by e-mail medisinsk.utstyr@helsedir.no or call the Norwegian Directorate of Health on +47 810 20 050 (switchboard).

Sist faglig oppdatert: 1. september 2016

skriv ut del på facebook del på twitter